title: Development of biomarkers to optimize pediatric patient management: what makes children different?
abstract: Despite the frequent utilization of biomarkers in medical practice, there is a relative paucity of information regarding validated pediatric biomarkers. Frequently, biomarkers found to be efficacious in adults are extrapolated to the pediatric clinical setting without considering that the pathogenesis of many diseases is distinctly different in children, and ontogeny directly influences disease evolution and therapeutic response in children. New and innovative approaches are necessary to provide reliable, validated biomarkers that can be used to improve and advance pediatric medical care.
authors: Division of Clinical Pharmacology & Medical Toxicology, Children's Mercy Hospitals & Clinics & University of Missouri-Kansas City, Kansas City, MO, USA.
authors: Jennifer
authors: J
authors: Goldman
authors: Mara L
authors: ML
authors: Becker
authors: Bridgette
authors: B
authors: Jones
authors: Mark
authors: M
authors: Clements
authors: J Steven
authors: JS
authors: Leeder
mesh_terms: D001171:Arthritis, Juvenile / Q000188:drug therapy; D015415:Biomarkers / Q000378:metabolism*; D002648:Child; D005492:Folic Acid / Q000378:metabolism; D005838:Genotype; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D010372:Pediatrics / Q000379:methods*; D010597:Pharmacogenetics; D012016:Reference Values
chemical_list: D015415:Biomarkers; D005492:Folic Acid; D008727:Methotrexate